Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Macitentan on Riociguat PK in Healthy Males
NCT03389321Phase 1Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Jan 2018
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of macitentan in pulmonary arterial hypertension (PAH), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoints: Area under the plasma concentration-time curve from zero to infinity of riociguat at Day 10 and Maximum plasma concentration of riociguat at Day 10. Started Jan 2018; status: completed.
02
Drugs
macitentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT03389321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03389321.